Spots Global Cancer Trial Database for A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Official Title: A Multicenter Phase 2, Single-Arm Open-Label Study of DCC-2618 to Assess Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors Who Have Progressed On Prior Anticancer Therapies
Study ID: NCT04633122
Conditions
Study Description
Brief Summary: the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with imatinib. This study will enroll approximately 98 subjects in around 18 sites in China mainland, and all subjects will be receiving DCC-2618 or Sunitinib in equal chance as treatment.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Cancer Hospital, Beijing, Beijing, China
Chinese PLA General Hospital, Beijing, Beijing, China
The General Hospital of Peking University, Beijing, Beijing, China
The First Affiliated Hospital of Chongqing Medical Universty, Chongqing, Chognqing, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
The Cancer Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
The sixth Affiliated hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
The 4th Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
The Affiliated Hospital of Haerbin MedicalUniversity, Ha'erbin, Heilongjiang, China
Union Hospital of HUST, Wuhan, Hubei, China
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Fudan University, Zhongshan Hospital, Shanghai, Shanghai, China
Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
West China Hospital of Sichuan University, Chengdu, Sichuan, China
The Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
